Cannabix Technologies Provides Update on Cannabis Breathalyzer and Spinout
March 02 2015 - 9:25AM
Access Wire
VANCOUVER, BC / ACCESSWIRE / March 2, 2015 /
Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF), is pleased
to announce it has produced an Alpha version of the Cannabix
Marijuana Breathalyzer prototype. Fabrication of prototype parts,
creation of firmware, circuit boards, electronics and detection
modules are all completed in the Alpha version. The Alpha version
of the Cannabix Marijuana Breathalyzer has been developed in
concert with KLN Klein Product Development Inc. of Vancouver,
B.C.
The Company will now
begin testing the device internally with medical marijuana users.
In addition, the Company is continuing to work with consultants and
scientists to maximize THC sensitivity, detection and reliability
of the device for use as a roadside or workplace drug impairment
tool.
Further modifications
may be made to enhance a range of components that make up the
device including optimization of THC detection levels, weather
proofing, calibration methods and other features. After internal
testing and development is complete with the Alpha prototype, the
Company will look to release a Beta version for trial testing with
external organizations. Trial testing externally (with independent
agencies) will help determine reliability, functionality and
accuracy of the device within a larger population of potential end
users.
Kal Malhi, President of
Cannabix Technologies stated, "We have initiated our internal
testing of the Alpha version of the breathalyzer prototype. We are
also excited to have commenced discussions with suitable
organizations for trial testing."
The Company reports that
the British Columbia Supreme Court has granted final approval of
the plan of arrangement to transfer 100% of the Monster Lake South
gold property to Spinco (Torino Ventures Inc.). Further details
with regards to a record date and closing of the plan of
arrangement will be forthcoming.
We seek Safe Harbor.
For more
information visit cannabixtechnologies.com
About Cannabix Technologies Inc.
Cannabix Technologies Inc.
is the developer of the patent pending Cannabix Marijuana
Breathalyzer for law enforcement and the workplace. The Cannabix
Marijuana Breathalyzer drug-impairment recognition system is based
on breath testing technology that has been developed to test
individuals for recent consumption of the THC component of
marijuana. Cannabix is advancing its products to enable law
enforcement personnel to use this technology to enhance detection
of marijuana impaired driving offences on North American roads at a
time when marijuana is becoming legal in many jurisdictions.
Cannabix is working to develop a drug-testing device that will
detect Tetrahydrocannabinol (THC- the psychoactive component of
marijuana that causes intoxication) using breath samples. The
device would be used to provide detection of THC at the roadside to
identify drivers intoxicated by the recent use of marijuana. The
device will also be useful for other practical applications such as
testing employees in the workplace where intoxication by THC can be
hazardous. The device is currently in prototype
development.
We seek
Safe Harbor.
On behalf of the Board of Directors
"Rav
Mlait"
CEO
Cannabix
Technologies Inc.
The CSE has not reviewed and does not accept
responsibility for the adequacy or accuracy of this
release.
Cautionary Statement Regarding Forward-Looking
Statements
This
press release contains forward-looking information that involves
various risks and uncertainties regarding future events. Such
forward-looking information can include without limitation
statements based on current expectations involving a number of
risks and uncertainties and are not guarantees of future
performance of the Company, such as final development of a
commercial or prototype product(s), successful trial or pilot of
company technologies, no assurance that commercial sales of any
kind actually materialize; no assurance the Company will have
sufficient funds to complete product development. There are
numerous risks and uncertainties that could cause actual results
and the Company's plans and objectives to differ materially from
those expressed in the forward-looking information, including: (i)
adverse market conditions; (ii) risks regarding protection of
proprietary technology; (iii) the ability of the Company to
complete financings; (v) the ability of the Company to develop and
market its future product; and (vi) risks regarding government
regulation, managing and maintaining growth, the effect of adverse
publicity, litigation, competition and other factors which may be
identified from time to time in the Company's public announcements
and filings. There is no assurance that the marijuana breathalyzer
business will provide any benefit to the Company, and no assurance
that any proposed new products will be built, work successfully or
proceed. There is no assurance that existing "patent pending"
technologies licensed by the Company will receive patent status by
regulatory authorities. The Company is not currently selling
commercial breathalyzers. Actual results and future events could
differ materially from those anticipated in such information. These
and all subsequent written and oral forward-looking information are
based on estimates and opinions of management on the dates they are
made and are expressly qualified in their entirety by this notice.
Except as required by law, the Company does not intend to update
these forward-looking statements.
SOURCE: Cannabix Technologies Inc.
Bullion Res (LSE:BLO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bullion Res (LSE:BLO)
Historical Stock Chart
From Apr 2023 to Apr 2024